Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Dar Global

    MCap

    USD1,486m

    Last close

    USD8.25

    ▲ −0.25 (−2.94%)

    Theon International

    MCap

    EUR875m

    Last close

    EUR12.50

    ▲ 1.44 (13.02%)

    Metals One

    MCap

    GBP2m

    Last close

    GBP0.00

    ▲ 0.04 (8.89%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Auris – executive interview

Auris – executive interview

Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase II) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase Ib). With AM-301, Auris is developing a nasal spray for protection against airborne pathogens and allergens.

In this video, Auris founder and chief executive officer Thomas Meyer provides an update on the company’s lead programs, AM-125 and AM-201, discussing recently received positive data and outlining key milestones for Q4 and 2021. Thomas also introduces the company’s new program, AM-301, and discusses the how the establishment of its new subsidiary, Altamira Medica, will support this ongoing development.

< Previous
Next >

You may also be interested in these:

Investment Companies

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

TMT

IP Group – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free